Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) EBITDA (2016 - 2025)

Marimed (MRMD) has disclosed EBITDA for 15 consecutive years, with -$4.5 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 208.24% to -$4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 192.36% year-over-year, with the annual reading at -$2.8 million for FY2025, 208.09% down from the prior year.
  • EBITDA for Q4 2025 was -$4.5 million at Marimed, down from $1.6 million in the prior quarter.
  • The five-year high for EBITDA was $12.0 million in Q2 2021, with the low at -$4.5 million in Q4 2025.
  • Average EBITDA over 5 years is $3.1 million, with a median of $2.8 million recorded in 2022.
  • The sharpest move saw EBITDA surged 598.68% in 2021, then plummeted 208.24% in 2025.
  • Over 5 years, EBITDA stood at $1.2 million in 2021, then skyrocketed by 156.77% to $3.1 million in 2022, then dropped by 21.95% to $2.4 million in 2023, then tumbled by 160.89% to -$1.5 million in 2024, then tumbled by 208.24% to -$4.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$4.5 million, $1.6 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.